Restricted TCR Valpha gene rearrangements in T cells recognizing an immunodominant peptide of myelin basic protein in DR2 patients with multiple sclerosis. 1998

Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
Department of Neurology and Baylor-Methodist International Multiple Sclerosis Center, Baylor College of Medicine, Veterans Affairs Medical Center, Houston, TX 77030, USA.

T cell responses to myelin basic protein (MBP) are thought to play an important role in the pathogenesis of multiple sclerosis (MS). The response to the 83-99 region of MBP represents a dominant response to MBP in patients with MS and is associated with HLA-DR2 that is linked with susceptibility to MS. Although T cell clones reactive to various regions of MBP have been found to exhibit heterogeneous TCR Vbeta gene usage in patients with MS, it is unclear whether T cell clones uniformly recognizing the 83-99 peptide of MBP in the context of the same DR molecule would have restricted TCR V gene rearrangements and recognition motifs. In this study, a panel of DR2- or DR4-restricted T cell clones specific for the MBP83-99 peptide were derived from 11 patients with MS and examined for TCR V gene usage by PCR and the recognition motifs using analog peptides. Our study revealed that despite a few T cell clone pairs having similar recognition motifs and shared sequence homology in the CDR3, the overall recognition motifs of MBP83-99-specific T cells were considerably diverse. Interestingly, the DR2-restricted T cell clones displayed a biased V gene usage for Valpha3 and Valpha8, while Vbeta gene rearrangements were highly heterogeneous. This study provided experimental evidence suggesting a limited heterogeneity in TCR Valpha gene rearrangements of MBP-reactive T cells in DR2 patients with MS.

UI MeSH Term Description Entries
D007135 Immunoglobulin Variable Region That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions. Variable Region, Ig,Variable Region, Immunoglobulin,Framework Region, Immunoglobulin,Fv Antibody Fragments,Fv Fragments,Ig Framework Region,Ig Variable Region,Immunoglobulin Framework Region,Immunoglobulin Fv Fragments,Immunoglobulin V,Antibody Fragment, Fv,Antibody Fragments, Fv,Fragment, Fv,Fragment, Fv Antibody,Fragment, Immunoglobulin Fv,Fragments, Fv,Fragments, Fv Antibody,Fragments, Immunoglobulin Fv,Framework Region, Ig,Framework Regions, Ig,Framework Regions, Immunoglobulin,Fv Antibody Fragment,Fv Fragment,Fv Fragment, Immunoglobulin,Fv Fragments, Immunoglobulin,Ig Framework Regions,Ig Variable Regions,Immunoglobulin Framework Regions,Immunoglobulin Fv Fragment,Immunoglobulin Variable Regions,Regions, Immunoglobulin Variable,Variable Regions, Ig,Variable Regions, Immunoglobulin
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004676 Myelin Basic Protein An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes. Golli-MBP1 Protein,Golli-MBP2 Protein,HOG5 Protein,HOG7 Protein,MBP1 Protein,MBP2 Protein,MBP3 Protein,MBP4 Protein,Myelin Basic Protein, 17.2 kDa Isoform,Myelin Basic Protein, 18.5 kDa Isoform,Myelin Basic Protein, 20.2 kDa Isoform,Myelin Basic Protein, 21.5 kDa Isoform,Myelin Basic Protein, Isoform 1,Myelin Basic Protein, Isoform 2,Myelin Basic Protein, Isoform 3,Myelin Basic Protein, Isoform 4,Myelin Basic Protein, Isoform 5,Myelin Basic Protein, Isoform 6,Myelin Basic Protein, Isoform 7,Golli MBP1 Protein,Golli MBP2 Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015332 Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors. T-Cell Antigen Receptor alpha-Chain Gene Rearrangement,T-Lymphocyte Antigen Receptor alpha-Chain Gene Rearrangement,Gene Rearrangement, alpha-Chain T Cell Antigen Receptor,T Cell alpha-Chain Gene Rearrangement,T Lymphocyte alpha-Chain Gene Rearrangement,Gene Rearrangement, alpha Chain T Cell Antigen Receptor,T Cell Antigen Receptor alpha Chain Gene Rearrangement,T Cell alpha Chain Gene Rearrangement,T Lymphocyte Antigen Receptor alpha Chain Gene Rearrangement,T Lymphocyte alpha Chain Gene Rearrangement
D015802 HLA-DR2 Antigen A broad specificity HLA-DR antigen that is associated with HLA-DRB1 CHAINS encoded by DRB1*01:15 and DRB1*01:16 alleles. HLA-DR2,Antigen, HLA-DR2,HLA DR2 Antigen

Related Publications

Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
April 1995, European journal of immunology,
Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
July 1990, Nature,
Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
April 1992, European journal of immunology,
Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
September 1997, The Journal of clinical investigation,
Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
February 1990, Science (New York, N.Y.),
Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
September 1995, Proceedings of the National Academy of Sciences of the United States of America,
Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
July 1995, Annals of the New York Academy of Sciences,
Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
February 1989, Journal of neuroscience research,
Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
January 1998, Research in immunology,
Y C Zang, and M Kozovska, and I Aebischer, and S Li, and S Boehme, and P Crowe, and V M Rivera, and J Z Zhang
November 1998, Journal of neuroimmunology,
Copied contents to your clipboard!